{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:54:51Z","timestamp":1780570491805,"version":"3.54.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["JOIO"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s43465-023-01063-6","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T08:03:48Z","timestamp":1701245028000},"page":"135-146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Biologics: Teriparatide and Newer Anabolics"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3113-9465","authenticated-orcid":false,"given":"Shiva Shankar","family":"Jha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"1063_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2147\/TCRM.S72456","volume":"10","author":"AS Nazrun","year":"2014","unstructured":"Nazrun, A. S., Tzar, M. N., Mokhtar, S. A., & Mohamed, I. N. (2014). A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Therapeutics and Clinical Risk Management, 10, 937\u2013948. https:\/\/doi.org\/10.2147\/TCRM.S72456","journal-title":"Therapeutics and Clinical Risk Management"},{"issue":"6","key":"1063_CR2","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00198-022-06657-8","volume":"34","author":"M Chandran","year":"2023","unstructured":"Chandran, M., Brind\u2019Amour, K., Fujiwara, S., Ha, Y. C., Tang, H., Hwang, J. S., Tinker, J., & Eisman, J. A. (2023). Prevalence of osteoporosis and incidence of related fractures in developed economies in the Asia Pacific region: a systematic review. Osteoporosis International, 34(6), 1037\u20131053. https:\/\/doi.org\/10.1007\/s00198-022-06657-8","journal-title":"Osteoporosis International"},{"issue":"1","key":"1063_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"T S\u00f6zen","year":"2017","unstructured":"S\u00f6zen, T., \u00d6z\u0131\u015f\u0131k, L., & Ba\u015faran, N. \u00c7. (2017). An overview and management of osteoporosis. European Journal of Rheumatology, 4(1), 46\u201356. https:\/\/doi.org\/10.5152\/eurjrheum.2016.048. Epub 2016 Dec 30.","journal-title":"European Journal of Rheumatology"},{"issue":"1","key":"1063_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","volume":"16","author":"N Salari","year":"2021","unstructured":"Salari, N., Ghasemi, H., Mohammadi, L., Behzadi, M. H., Rabieenia, E., Shohaimi, S., & Mohammadi, M. (2021). The global prevalence of osteoporosis in the world: A comprehensive systematic review and meta-analysis. Journal of Orthopaedic Surgery and Research, 16(1), 609. https:\/\/doi.org\/10.1186\/s13018-021-02772-0","journal-title":"Journal of Orthopaedic Surgery and Research"},{"issue":"7","key":"1063_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1089\/jwh.2013.4611","volume":"23","author":"JM Kling","year":"2014","unstructured":"Kling, J. M., Clarke, B. L., & Sandhu, N. P. (2014). Osteoporosis prevention, screening, and treatment: a review. Journal of Women\u2019s Health (Larchmt), 23(7), 563\u2013572. https:\/\/doi.org\/10.1089\/jwh.2013.4611","journal-title":"Journal of Women's Health (Larchmt)"},{"issue":"2","key":"1063_CR6","first-page":"92","volume":"43","author":"KN Tu","year":"2018","unstructured":"Tu, K. N., Lie, J. D., Wan, C. K. V., Cameron, M., Austel, A. G., Nguyen, J. K., Van, K., & Hyun, D. (2018). Osteoporosis: a review of treatment options. Pharmacy and Therapeutics, 43(2), 92\u2013104.","journal-title":"Pharmacy and Therapeutics"},{"issue":"11","key":"1063_CR7","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00228-014-1735-5","volume":"70","author":"SH Tella","year":"2014","unstructured":"Tella, S. H., & Gallagher, J. C. (2014). Biological agents in management of osteoporosis. Eur J ClinPharmacol., 70(11), 1291\u20131301. https:\/\/doi.org\/10.1007\/s00228-014-1735-5","journal-title":"Eur J ClinPharmacol."},{"key":"1063_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/bonekey.2014.24.PMID:24876930;PMCID:PMC4037878","volume":"3","author":"M Pazianas","year":"2014","unstructured":"Pazianas, M., van der Geest, S., & Miller, P. (2014). Bisphosphonates and bone quality. Bonekey Rep., 3, 529. https:\/\/doi.org\/10.1038\/bonekey.2014.24.PMID:24876930;PMCID:PMC4037878","journal-title":"Bonekey Rep."},{"issue":"20","key":"1063_CR9","doi-asserted-by":"publisher","first-page":"7623","DOI":"10.3390\/ijms21207623","volume":"21","author":"JY Noh","year":"2020","unstructured":"Noh, J. Y., Yang, Y., & Jung, H. (2020). Molecular mechanisms and emerging therapeutics for osteoporosis. International Journal of Molecular Sciences, 21(20), 7623. https:\/\/doi.org\/10.3390\/ijms21207623","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"1063_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11420-015-9469-1","volume":"12","author":"JC Villa","year":"2016","unstructured":"Villa, J. C., Gianakos, A., & Lane, J. M. (2016). Bisphosphonate treatment in osteoporosis: optimal duration of therapy and the incorporation of a drug holiday. HSS Journal, 12(1), 66\u201373. https:\/\/doi.org\/10.1007\/s11420-015-9469-1. Epub 2015 Dec 9.","journal-title":"HSS Journal"},{"key":"1063_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fcell.2020.00325","volume":"8","author":"N Zhang","year":"2020","unstructured":"Zhang, N., Zhang, Z. K., Yu, Y., Zhuo, Z., Zhang, G., & Zhang, B. T. (2020). Pros and cons of denosumab treatment for osteoporosis and implication for RANKL aptamer therapy. Frontiers in Cell and Developmental Biology, 8, 325. https:\/\/doi.org\/10.3389\/fcell.2020.00325","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"6","key":"1063_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2021.101551","volume":"35","author":"A Gosset","year":"2021","unstructured":"Gosset, A., Pouill\u00e8s, J. M., & Tr\u00e9mollieres, F. (2021). Menopausal hormone therapy for the management of osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism, 35(6), 101551. https:\/\/doi.org\/10.1016\/j.beem.2021.101551","journal-title":"Best Practice & Research Clinical Endocrinology & Metabolism"},{"issue":"2","key":"1063_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1590\/s0004-27302010000200016","volume":"54","author":"J Kulak J\u00fanior","year":"2010","unstructured":"Kulak J\u00fanior, J., Kulak, C. A., & Taylor, H. S. (2010). SERMs in the prevention and treatment of postmenopausal osteoporosis: an update. Arquivos Brasileiros de Endocrinologia & Metabologia, 54(2), 200\u2013205. https:\/\/doi.org\/10.1590\/s0004-27302010000200016","journal-title":"Arquivos Brasileiros de Endocrinologia & Metabologia"},{"issue":"4","key":"1063_CR14","doi-asserted-by":"publisher","first-page":"D13","DOI":"10.1530\/EJE-18-0113","volume":"178","author":"I Chiodini","year":"2018","unstructured":"Chiodini, I., & Bolland, M. J. (2018). Calcium supplementation in osteoporosis: useful or harmful? European Journal of Endocrinology, 178(4), D13\u2013D25. https:\/\/doi.org\/10.1530\/EJE-18-0113","journal-title":"European Journal of Endocrinology"},{"issue":"12","key":"1063_CR15","doi-asserted-by":"publisher","first-page":"10817","DOI":"10.1039\/d0fo00787k","volume":"11","author":"C Liu","year":"2020","unstructured":"Liu, C., Kuang, X., Li, K., Guo, X., Deng, Q., & Li, D. (2020). Effects of combined calcium and vitamin D supplementation on osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Food & Function, 11(12), 10817\u201310827. https:\/\/doi.org\/10.1039\/d0fo00787k","journal-title":"Food & Function"},{"issue":"2","key":"1063_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00024677-200403020-00005","volume":"3","author":"TE Vogelvang","year":"2004","unstructured":"Vogelvang, T. E., van der Mooren, M. J., & Mijatovic, V. (2004). Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications. Treatments in Endocrinology, 3(2), 105\u2013115. https:\/\/doi.org\/10.2165\/00024677-200403020-00005","journal-title":"Treatments in Endocrinology"},{"issue":"7","key":"1063_CR17","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1210\/jc.2012-1027","volume":"97","author":"S Khosla","year":"2012","unstructured":"Khosla, S., Bilezikian, J. P., Dempster, D. W., Lewiecki, E. M., Miller, P. D., Neer, R. M., Recker, R. R., Shane, E., Shoback, D., & Potts, J. T. (2012). Benefits and risks of bisphosphonate therapy for osteoporosis. J ClinEndocrinolMetab., 97(7), 2272\u20132282. https:\/\/doi.org\/10.1210\/jc.2012-1027","journal-title":"J ClinEndocrinolMetab."},{"issue":"3","key":"1063_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1517\/17425255.2015.1000860","volume":"11","author":"S Zaheer","year":"2015","unstructured":"Zaheer, S., LeBoff, M., & Lewiecki, E. M. (2015). Denosumab for the treatment of osteoporosis. Expert Opin Drug MetabToxicol., 11(3), 461\u2013470. https:\/\/doi.org\/10.1517\/17425255.2015.1000860. Epub 2015 Jan 22.","journal-title":"Expert Opin Drug MetabToxicol."},{"issue":"2","key":"1063_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/er.2007-0014","volume":"29","author":"AE Kearns","year":"2008","unstructured":"Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008). Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocrine Reviews, 29(2), 155\u2013192. https:\/\/doi.org\/10.1210\/er.2007-0014. Epub 2007 Dec 5.","journal-title":"Endocrine Reviews"},{"issue":"4","key":"1063_CR20","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jama.292.4.490","volume":"292","author":"LC Hofbauer","year":"2004","unstructured":"Hofbauer, L. C., & Schoppet, M. (2004). Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases. JAMA, 292(4), 490\u2013495. https:\/\/doi.org\/10.1001\/jama.292.4.490","journal-title":"JAMA"},{"issue":"5","key":"1063_CR21","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/s0002-9440(10)63560-2","volume":"163","author":"E Grimaud","year":"2003","unstructured":"Grimaud, E., Soubigou, L., Couillaud, S., Coipeau, P., Moreau, A., Passuti, N., Gouin, F., Redini, F., & Heymann, D. (2003). Receptor activator of nuclear factor kappaB ligand (RANKL)\/osteoprotegerin (OPG) ratio is increased in severe osteolysis. American Journal of Pathology, 163(5), 2021\u20132031. https:\/\/doi.org\/10.1016\/s0002-9440(10)63560-2","journal-title":"American Journal of Pathology"},{"issue":"2","key":"1063_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","volume":"473","author":"BF Boyce","year":"2008","unstructured":"Boyce, B. F., & Xing, L. (2008). Functions of RANKL\/RANK\/OPG in bone modeling and remodeling. Arch BiochemBiophys., 473(2), 139\u2013146. https:\/\/doi.org\/10.1016\/j.abb.2008.03.018. Epub 2008 Mar 25.","journal-title":"Arch BiochemBiophys."},{"key":"1063_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/TCRM.S24239","volume":"8","author":"AD Anastasilakis","year":"2012","unstructured":"Anastasilakis, A. D., Toulis, K. A., Polyzos, S. A., Anastasilakis, C. D., & Makras, P. (2012). Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. TherClin Risk Manag., 8, 295\u2013306. https:\/\/doi.org\/10.2147\/TCRM.S24239. Epub 2012 Jun 19.","journal-title":"TherClin Risk Manag."},{"issue":"Suppl 1","key":"1063_CR24","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/ar2167","volume":"9","author":"M McClung","year":"2007","unstructured":"McClung, M. (2007). Role of RANKL inhibition in osteoporosis. Arthritis Research & Therapy, 9(Suppl 1), S3. https:\/\/doi.org\/10.1186\/ar2167","journal-title":"Arthritis Research & Therapy"},{"issue":"4","key":"1063_CR25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s11914-013-0171-2","volume":"11","author":"M Augustine","year":"2013","unstructured":"Augustine, M., & Horwitz, M. J. (2013). Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis. Current Osteoporosis Reports, 11(4), 400\u2013406. https:\/\/doi.org\/10.1007\/s11914-013-0171-2","journal-title":"Current Osteoporosis Reports"},{"issue":"3","key":"1063_CR26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1185\/03007995.2012.659724","volume":"28","author":"A Migliore","year":"2012","unstructured":"Migliore, A., Broccoli, S., Massafra, U., Bizzi, E., & Frediani, B. (2012). Mixed-treatment comparison of anabolic (teriparatide and PTH 1\u201384) therapies in women with severe osteoporosis. Current Medical Research and Opinion, 28(3), 467\u2013473. https:\/\/doi.org\/10.1185\/03007995.2012.659724","journal-title":"Current Medical Research and Opinion"},{"issue":"5","key":"1063_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1358\/dot.2018.54.5.2800621","volume":"54","author":"L Pietrogrande","year":"2018","unstructured":"Pietrogrande, L., & Raimondo, E. (2018). Abaloparatide for the treatment of postmenopausal osteoporosis. Drugs of Today (Barcelona, Spain), 54(5), 293\u2013303. https:\/\/doi.org\/10.1358\/dot.2018.54.5.2800621","journal-title":"Drugs of Today (Barcelona, Spain)"},{"issue":"7","key":"1063_CR28","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller, P. D., Hattersley, G., Riis, B. J., Williams, G. C., Lau, E., Russo, L. A., Alexandersen, P., Zerbini, C. A., Hu, M. Y., Harris, A. G., Fitzpatrick, L. A., Cosman, F., Christiansen, C., ACTIVE Study Investigators. (2016). Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA, 316(7), 722\u2013733. https:\/\/doi.org\/10.1001\/jama.2016.11136. Erratum in: JAMA. 2017;317(4):442.","journal-title":"JAMA"},{"issue":"9999","key":"1063_CR29","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder, B. Z., Tsai, J. N., Uihlein, A. V., Wallace, P. M., Lee, H., Neer, R. M., & Burnett-Bowie, S. A. (2015). Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet, 386(9999), 1147\u20131155. https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5. Epub 2015 Jul 2.","journal-title":"Lancet"},{"issue":"3","key":"1063_CR30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.drudis.2013.07.015","volume":"19","author":"T Ponnapakkam","year":"2014","unstructured":"Ponnapakkam, T., Katikaneni, R., Sakon, J., Stratford, R., & Gensure, R. C. (2014). Treating osteoporosis by targeting parathyroid hormone to bone. Drug Discovery Today, 19(3), 204\u2013208. https:\/\/doi.org\/10.1016\/j.drudis.2013.07.015. Epub 2013 Aug 6.","journal-title":"Drug Discovery Today"},{"issue":"3","key":"1063_CR31","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1210\/jc.2009-0233","volume":"95","author":"MJ Horwitz","year":"2010","unstructured":"Horwitz, M. J., Tedesco, M. B., Garcia-Oca\u00f1a, A., Sereika, S. M., Prebehala, L., Bisello, A., Hollis, B. W., Gundberg, C. M., & Stewart, A. F. (2010). Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. The Journal of Clinical Endocrinology & Metabolism, 95(3), 1279\u20131287. https:\/\/doi.org\/10.1210\/jc.2009-0233","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"3","key":"1063_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.maturitas.2014.04.013","volume":"78","author":"SC Manolagas","year":"2014","unstructured":"Manolagas, S. C. (2014). Wnt signalling and osteoporosis. Maturitas, 78(3), 233\u2013237. https:\/\/doi.org\/10.1016\/j.maturitas.2014.04.013. Epub 2014 Apr 24.","journal-title":"Maturitas"},{"issue":"4","key":"1063_CR33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s11914-008-0025-5","volume":"6","author":"M Shahnazari","year":"2008","unstructured":"Shahnazari, M., Yao, W., Corr, M., & Lane, N. E. (2008). Targeting the Wnt signalling pathway to augment bone formation. Current Osteoporosis Reports, 6(4), 142\u2013148. https:\/\/doi.org\/10.1007\/s11914-008-0025-5","journal-title":"Current Osteoporosis Reports"},{"issue":"3","key":"1063_CR34","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1182\/blood-2008-03-145169","volume":"113","author":"JJ Pinzone","year":"2009","unstructured":"Pinzone, J. J., Hall, B. M., Thudi, N. K., Vonau, M., Qiang, Y. W., Rosol, T. J., & Shaughnessy, J. D., Jr. (2009). The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood, 113(3), 517\u2013525. https:\/\/doi.org\/10.1182\/blood-2008-03-145169. Epub 2008 Aug 7.","journal-title":"Blood"},{"issue":"3","key":"1063_CR35","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/jcm11030806","volume":"11","author":"ES Vasiliadis","year":"2022","unstructured":"Vasiliadis, E. S., Evangelopoulos, D. S., Kaspiris, A., Benetos, I. S., Vlachos, C., & Pneumaticos, S. G. (2022). The role of sclerostin in bone diseases. Journal of Clinical Medicine, 11(3), 806. https:\/\/doi.org\/10.3390\/jcm11030806","journal-title":"Journal of Clinical Medicine"},{"issue":"5","key":"1063_CR36","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.apsb.2022.01.012","volume":"12","author":"S Yu","year":"2022","unstructured":"Yu, S., Li, D., Zhang, N., Ni, S., Sun, M., Wang, L., Xiao, H., Liu, D., Liu, J., Yu, Y., Zhang, Z., Yeung, S. T. Y., Zhang, S., Lu, A., Zhang, Z., Zhang, B., & Zhang, G. (2022). Drug discovery of sclerostin inhibitors. Acta Pharmaceutica Sinica B, 12(5), 2150\u20132170. https:\/\/doi.org\/10.1016\/j.apsb.2022.01.012","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"3","key":"1063_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.maturitas.2014.04.016","volume":"78","author":"BL Clarke","year":"2014","unstructured":"Clarke, B. L. (2014). Anti-sclerostin antibodies: utility in treatment of osteoporosis. Maturitas, 78(3), 199\u2013204. https:\/\/doi.org\/10.1016\/j.maturitas.2014.04.016","journal-title":"Maturitas"},{"key":"1063_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejphar.2018.02.028","volume":"826","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya, S., Pal, S., & Chattopadhyay, N. (2018). Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: a critical assessment of the mechanism of action. European Journal of Pharmacology, 826, 39\u201347. https:\/\/doi.org\/10.1016\/j.ejphar.2018.02.028","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"1063_CR39","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/jcph.239","volume":"54","author":"D Padhi","year":"2014","unstructured":"Padhi, D., Allison, M., Kivitz, A. J., Gutierrez, M. J., Stouch, B., Wang, C., & Jang, G. (2014). Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study. The Journal of Clinical Pharmacology, 54(2), 168\u2013178. https:\/\/doi.org\/10.1002\/jcph.239","journal-title":"The Journal of Clinical Pharmacology"},{"issue":"2","key":"1063_CR40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/jbmr.2351","volume":"30","author":"RR Recker","year":"2015","unstructured":"Recker, R. R., Benson, C. T., Matsumoto, T., Bolognese, M. A., Robins, D. A., Alam, J., Chiang, A. Y., Hu, L., Krege, J. H., Sowa, H., Mitlak, B. H., & Myers, S. L. (2015). A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. Journal of Bone and Mineral Research, 30(2), 216\u2013224. https:\/\/doi.org\/10.1002\/jbmr.2351","journal-title":"Journal of Bone and Mineral Research"},{"issue":"16","key":"1063_CR41","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., Zerbini, C. A., Milmont, C. E., Chen, L., Maddox, J., Meisner, P. D., Libanati, C., & Grauer, A. (2016). Romosozumab treatment in postmenopausal women with osteoporosis. New England Journal of Medicine, 375(16), 1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"1063_CR42","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.21037\/apm-22-998","volume":"11","author":"Y Su","year":"2022","unstructured":"Su, Y., Wang, W., Liu, F., Cai, Y., Li, N., Li, H., Li, G., & Ma, L. (2022). Blosozumab in the treatment of postmenopausal women with osteoporosis: A systematic review and meta-analysis. Annals of Palliative Medicine, 11(10), 3203\u20133212. https:\/\/doi.org\/10.21037\/apm-22-998","journal-title":"Annals of Palliative Medicine"},{"issue":"1","key":"1063_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.tem.2012.10.003","volume":"24","author":"DM Joiner","year":"2013","unstructured":"Joiner, D. M., Ke, J., Zhong, Z., Xu, H. E., & Williams, B. O. (2013). LRP5 and LRP6 in development and disease. Trends in Endocrinology & Metabolism, 24(1), 31\u201339. https:\/\/doi.org\/10.1016\/j.tem.2012.10.003","journal-title":"Trends in Endocrinology & Metabolism"},{"issue":"8","key":"1063_CR44","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1242\/dev.01117","volume":"131","author":"X He","year":"2004","unstructured":"He, X., Semenov, M., Tamai, K., & Zeng, X. (2004). LDL receptor-related proteins 5 and 6 in Wnt\/beta-catenin signalling: arrows point the way. Development, 131(8), 1663\u20131677. https:\/\/doi.org\/10.1242\/dev.01117","journal-title":"Development"},{"issue":"13","key":"1063_CR45","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2174\/13894501113149990202","volume":"14","author":"AM Helali","year":"2013","unstructured":"Helali, A. M., Iti, F. M., & Mohamed, I. N. (2013). Cathepsin K inhibitors: a novel target but promising approach in the treatment of osteoporosis. Current Drug Targets, 14(13), 1591\u20131600. https:\/\/doi.org\/10.2174\/13894501113149990202","journal-title":"Current Drug Targets"},{"issue":"22","key":"1063_CR46","doi-asserted-by":"publisher","first-page":"13762","DOI":"10.3390\/ijms232213762","volume":"23","author":"O Mijanovic","year":"2022","unstructured":"Mijanovic, O., Jakovleva, A., Brankovi\u0107, A., Zdravkova, K., Pualic, M., Belozerskaya, T. A., Nikitkina, A. I., Parodi, A., & Zamyatnin, A. A., Jr. (2022). Cathepsin K in pathological conditions and new therapeutic and diagnostic perspectives. International Journal of Molecular Sciences, 23(22), 13762. https:\/\/doi.org\/10.3390\/ijms232213762","journal-title":"International Journal of Molecular Sciences"},{"issue":"5","key":"1063_CR47","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1517\/13543780902832661","volume":"18","author":"D Bromme","year":"2009","unstructured":"Bromme, D., & Lecaille, F. (2009). Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opinion on Investigational Drugs., 18(5), 585\u2013600. https:\/\/doi.org\/10.1517\/13543780902832661","journal-title":"Expert Opinion on Investigational Drugs."},{"issue":"1","key":"1063_CR48","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1080\/14756366.2018.1465417","volume":"33","author":"J Lu","year":"2018","unstructured":"Lu, J., Wang, M., Wang, Z., Fu, Z., Lu, A., & Zhang, G. (2018). Advances in the discovery of cathepsin K inhibitors on bone resorption. Journal of Enzyme Inhibition and Medicinal Chemistry, 33(1), 890\u2013904. https:\/\/doi.org\/10.1080\/14756366.2018.1465417","journal-title":"Journal of Enzyme Inhibition and Medicinal Chemistry"},{"issue":"4","key":"1063_CR49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1210\/er.2015-1114","volume":"38","author":"MT Drake","year":"2017","unstructured":"Drake, M. T., Clarke, B. L., Oursler, M. J., & Khosla, S. (2017). Cathepsin K Inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned. Endocrine Reviews, 38(4), 325\u2013350. https:\/\/doi.org\/10.1210\/er.2015-1114","journal-title":"Endocrine Reviews"},{"key":"1063_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bcp.2016.04.010","volume":"117","author":"K Mukherjee","year":"2016","unstructured":"Mukherjee, K., & Chattopadhyay, N. (2016). Pharmacological inhibition of cathepsin K: a promising novel approach for postmenopausal osteoporosis therapy. Biochemical Pharmacology., 117, 10\u201319. https:\/\/doi.org\/10.1016\/j.bcp.2016.04.010","journal-title":"Biochemical Pharmacology."},{"issue":"11","key":"1063_CR51","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1517\/14656566.2015.1064897","volume":"16","author":"MK Boggild","year":"2015","unstructured":"Boggild, M. K., Gajic-Veljanoski, O., McDonald-Blumer, H., Ridout, R., Tile, L., Josse, R., & Cheung, A. M. (2015). Odanacatib for the treatment of osteoporosis. Expert Opinion on Pharmacotherapy, 16(11), 1717\u20131726. https:\/\/doi.org\/10.1517\/14656566.2015.1064897","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"12","key":"1063_CR52","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S2213-8587(19)30346-8","volume":"7","author":"MR McClung","year":"2019","unstructured":"McClung, M. R., O\u2019Donoghue, M. L., Papapoulos, S. E., Bone, H., Langdahl, B., Saag, K. G., Reid, I. R., Kiel, D. P., Cavallari, I., Bonaca, M. P., Wiviott, S. D., de Villiers, T., Ling, X., Lippuner, K., Nakamura, T., Reginster, J. Y., Rodriguez-Portales, J. A., Roux, C., Zanchetta, J., \u2026 Sabatine, M. S. (2019). Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. The Lancet Diabetes & Endocrinology., 7(12), 899\u2013911. https:\/\/doi.org\/10.1016\/S2213-8587(19)30346-8","journal-title":"The Lancet Diabetes & Endocrinology."},{"issue":"3","key":"1063_CR53","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/j.jaad.2010.11.033","volume":"66","author":"TM Runger","year":"2012","unstructured":"Runger, T. M., Adami, S., Benhamou, C. L., Czerwi\u0144ski, E., Farrerons, J., Kendler, D. L., Mindeholm, L., Realdi, G., Roux, C., & Smith, V. (2012). Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. Journal of the American Academy of Dermatology, 66(3), e89-96. https:\/\/doi.org\/10.1016\/j.jaad.2010.11.033","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"1063_CR54","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/diagnostics10030145","volume":"10","author":"FF Ramli","year":"2020","unstructured":"Ramli, F. F., & Chin, K. Y. (2020). A review of the potential application of osteocyte-related biomarkers, fibroblast growth factor-23, Sclerostin, and Dickkopf-1 in predicting osteoporosis and fractures. Diagnostics (Basel)., 10(3), 145. https:\/\/doi.org\/10.3390\/diagnostics10030145","journal-title":"Diagnostics (Basel)."},{"issue":"7","key":"1063_CR55","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/biomedicines9070736","volume":"9","author":"T Katagiri","year":"2021","unstructured":"Katagiri, T., Tsukamoto, S., & Kuratani, M. (2021). Accumulated knowledge of activin receptor-like kinase 2 (ALK2)\/activin A receptor, type 1 (ACVR1) as a target for human disorders. Biomedicines., 9(7), 736. https:\/\/doi.org\/10.3390\/biomedicines9070736","journal-title":"Biomedicines."},{"issue":"5","key":"1063_CR56","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.3390\/ijms23052500","volume":"23","author":"W Sirikul","year":"2022","unstructured":"Sirikul, W., Siri-Angkul, N., Chattipakorn, N., & Chattipakorn, S. C. (2022). Fibroblast growth factor 23 and osteoporosis: evidence from bench to bedside. International Journal of Molecular Sciences, 23(5), 2500. https:\/\/doi.org\/10.3390\/ijms23052500","journal-title":"International Journal of Molecular Sciences"},{"issue":"11","key":"1063_CR57","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/jcph.1638","volume":"60","author":"F Vanhoutte","year":"2020","unstructured":"Vanhoutte, F., Liang, S., Ruddy, M., Zhao, A., Drewery, T., Wang, Y., DelGizzi, R., Forleo-Neto, E., Rajadhyaksha, M., Herman, G., & Davis, J. D. (2020). Pharmacokinetics and pharmacodynamics of garetosmab (anti-activin A): Results from a first-in-human phase 1 study. The Journal of Clinical Pharmacology, 60(11), 1424\u20131431. https:\/\/doi.org\/10.1002\/jcph.1638","journal-title":"The Journal of Clinical Pharmacology"},{"key":"1063_CR58","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s40064-016-1892-3","volume":"5","author":"R Dent","year":"2016","unstructured":"Dent, R., Joshi, R., Stephen Djedjos, C., Legg, J., Elliott, M., Geller, M., Meyer, D., Somaratne, R., Recknor, C., & Weiss, R. (2016). Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting. Springerplus, 5, 300. https:\/\/doi.org\/10.1186\/s40064-016-1892-3","journal-title":"Springerplus"},{"issue":"8","key":"1063_CR59","doi-asserted-by":"publisher","first-page":"e005639","DOI":"10.1161\/JAHA.117.005639","volume":"6","author":"HE Bays","year":"2017","unstructured":"Bays, H. E., Leiter, L. A., Colhoun, H. M., Thompson, D., Bessac, L., Pordy, R., & Toth, P. P. (2017). Alirocumab treatment and achievement of non-high-density lipoprotein cholesterol and apolipoprotein B goals in patients with hypercholesterolemia: Pooled results from 10 phase 3 ODYSSEY trials. Journal of the American Heart Association, 6(8), e005639. https:\/\/doi.org\/10.1161\/JAHA.117.005639","journal-title":"Journal of the American Heart Association"},{"issue":"2","key":"1063_CR60","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00223-023-01085-0","volume":"113","author":"F Lv","year":"2023","unstructured":"Lv, F., Cai, X., Lin, C., Yang, W., Hu, S., & Ji, L. (2023). Proprotein convertase subtilisin\/kexin type 9 inhibitors and the risk of fracture: a systematic review and meta-analysis of randomized controlled trials. Calcified Tissue International, 113(2), 175\u2013185. https:\/\/doi.org\/10.1007\/s00223-023-01085-0","journal-title":"Calcified Tissue International"},{"issue":"6","key":"1063_CR61","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4239\/wjd.v7.i6.122","volume":"7","author":"AD McCarthy","year":"2016","unstructured":"McCarthy, A. D., Cortizo, A. M., & Sedlinsky, C. (2016). Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy. World Journal of Diabetes, 7(6), 122\u2013133. https:\/\/doi.org\/10.4239\/wjd.v7.i6.122","journal-title":"World Journal of Diabetes"},{"issue":"23","key":"1063_CR62","doi-asserted-by":"publisher","first-page":"9004","DOI":"10.3390\/ijms21239004","volume":"21","author":"A Damerau","year":"2020","unstructured":"Damerau, A., Gaber, T., Ohrndorf, S., & Hoff, P. (2020). JAK\/STAT activation: a general mechanism for bone development, homeostasis, and regeneration. International Journal of Molecular Sciences, 21(23), 9004. https:\/\/doi.org\/10.3390\/ijms21239004","journal-title":"International Journal of Molecular Sciences"},{"key":"1063_CR63","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/bonekey.2014.13","volume":"3","author":"F Cosman","year":"2014","unstructured":"Cosman, F. (2014). Combination therapy for osteoporosis: A reappraisal. Bonekey Reports., 3, 518. https:\/\/doi.org\/10.1038\/bonekey.2014.13","journal-title":"Bonekey Reports."},{"issue":"2","key":"1063_CR64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1017\/S002966510800699X","volume":"67","author":"R Eastell","year":"2008","unstructured":"Eastell, R., & Hannon, R. A. (2008). Biomarkers of bone health and osteoporosis risk. The Proceedings of the Nutrition Society, 67(2), 157\u2013162. https:\/\/doi.org\/10.1017\/S002966510800699X","journal-title":"The Proceedings of the Nutrition Society"},{"issue":"2","key":"1063_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e13323","volume":"9","author":"A Bodaghi","year":"2023","unstructured":"Bodaghi, A., Fattahi, N., & Ramazani, A. (2023). Biomarkers: promising and valuable tools towards diagnosis, prognosis and treatment of COVID-19 and other diseases. Heliyon., 9(2), e13323. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e13323","journal-title":"Heliyon."},{"issue":"3","key":"1063_CR66","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1535370217750088","volume":"243","author":"RM Califf","year":"2018","unstructured":"Califf, R. M. (2018). Biomarker definitions and their applications. Experimental Biology and Medicine (Maywood)., 243(3), 213\u2013221. https:\/\/doi.org\/10.1177\/1535370217750088","journal-title":"Experimental Biology and Medicine (Maywood)."}],"container-title":["Indian Journal of Orthopaedics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43465-023-01063-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43465-023-01063-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43465-023-01063-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T07:04:21Z","timestamp":1702537461000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43465-023-01063-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":66,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1063"],"URL":"https:\/\/doi.org\/10.1007\/s43465-023-01063-6","relation":{},"ISSN":["0019-5413","1998-3727"],"issn-type":[{"value":"0019-5413","type":"print"},{"value":"1998-3727","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]},"assertion":[{"value":"27 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by the any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study informed consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}